Adam JacksonNovember 27, 2023
Positive study results could prompt Seelos to seek FDA approval for its drug.
Tag: Seelos Therapeutics
Adam JacksonNovember 27, 2023Adam JacksonSeptember 22, 2023
Cantor Fitzgerald, in reaction to the news, downgraded the stock.
Debra BorchardtMay 16, 2023
CEO: "2023 is the most important year in Seelos' history thus far."
Adam JacksonApril 5, 2023
The company's portfolio includes several late-stage clinical assets.
Debra BorchardtFebruary 13, 2023
Seelos expects to launch an expanded access program for the treatment later this quarter.
Dave HodesOctober 31, 2022
Novel treatments are required. That’s where psychedelics come in.
Dave HodesSeptember 7, 2022
Any analyst knows that market-reactive swings aren’t really a true indicator of what is going on inside a company.
StaffMarch 7, 2022
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its year-end 2021 business and clinical update. In the second half of 2021, Seelos said it had achieved several major clinical and financial milestones and continued to make progress on its multiple clinical-stage development programs. As of year-end 2021, Seelos had $78.7mm of cash. SLS-002 (intranasal racemic ketamine) In July, Seelos began […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.